Islet Amyloid Polypeptide in Patients with Pancreatic Cancer and Diabetes
Open Access
- 3 February 1994
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 330 (5) , 313-318
- https://doi.org/10.1056/nejm199402033300503
Abstract
The diabetes mellitus that occurs in patients with pancreatic cancer is characterized by marked insulin resistance that declines after tumor resection. Islet amyloid polypeptide (IAPP), a hormonal factor secreted from the pancreatic beta cells, reduces insulin sensitivity in vivo and glycogen synthesis in vitro. In this study, we examined the relation between IAPP and diabetes in patients with pancreatic cancer. We measured IAPP in plasma from 30 patients with pancreatic cancer, 46 patients with other cancers, 23 patients with diabetes, and 25 normal subjects. IAPP immunoreactivity and IAPP messenger RNA were studied in pancreatic cancers, pancreatic tissue adjacent to cancers, and normal pancreatic tissue. Plasma IAPP concentrations were elevated in the patients with pancreatic cancer as compared with the normal subjects (mean [±SD], 22.3 ±13.6 vs. 8.0 ±5.0 pmol per liter; P<0.001), normal in the patients with other cancers, and normal or low in the patients with diabetes. Among the patients with pancreatic cancer, the concentrations were 25.0 ±8.7 pmol per liter in the 7 patients with diabetes who required insulin, 31.4 ±12.6 pmol per liter in the 11 patients with diabetes who did not require insulin, and 12.2 ±2.4 pmol per liter in the 9 patients with normal glucose tolerance (3 patients had impaired glucose tolerance; their mean plasma IAPP concentration was 11.7 ±5.5 pmol per liter). Plasma IAPP concentrations decreased after surgery in the seven patients with pancreatic cancer who were studied before and after subtotal pancreatectomy (28.9 ±16.4 vs. 5.6 ±3.4 pmol per liter, P = 0.01). Pancreatic cancers contained IAPP, but the concentrations were lower than in normal pancreatic tissue (17 ±16 vs. 183 ±129 pmol per gram, P<0.001). In samples from the patients with both pancreatic cancer and diabetes, immunostaining for IAPP was reduced in islets of pancreatic tissue surrounding the tumor; in situ hybridization studies suggested that transcription occurred normally in these islets. Plasma IAPP concentrations are elevated in patients with pancreatic cancer who have diabetes. Since IAPP may cause insulin resistance, its overproduction may contribute to the diabetes that occurs in these patients.Keywords
This publication has 23 references indexed in Scilit:
- Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancerBritish Journal of Surgery, 1993
- Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor?The American Journal of Surgery, 1993
- Amylin inhibits insulin-stimulated glucose uptake in C2C12 muscle cell line through a cholera-toxin-sensitive mechanismBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992
- Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in manJournal of Clinical Endocrinology & Metabolism, 1992
- Anorexia following the intrahypothalamic administration of amylinBrain Research, 1991
- Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humansDiabetes, 1990
- Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitroNature, 1988
- A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinomaDigestive Diseases and Sciences, 1978
- Radioimmunological determination of human C-peptide in serumDiabetologia, 1975
- THE INTRAVENOUS TOLBUTAMIDE TEST AS A DIAGNOSTIC AID IN CARCINOMA OF THE PANCREASThe Lancet Healthy Longevity, 1962